# Iambic Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iambic-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.iambic.ai
- Total disclosed funding: $267M
- Latest round: Series B (Nov 6, 2025)
- Investors on record: 24

## About

Founded in 2019 and based in California, US, Iambic Therapeutics, Inc. operates as a healthcare technology company that offers a platform that combines machine learning and automated synthetic development to design small-molecule therapeutics. In November 2025, Iambic Therapeutics, Inc. raised USD 100 million in venture funding from new investors Abingworth, Alexandria Venture Investments, Ark Invest, Pegasus Tech Ventures, Regeneron Ventures, Terra Magnum Capital Partners, WS Investments, and Everbright Biofund. Returning investors Alumni Ventures Group, Ascenta Capital, Catalio Capital Management, Freeflow Ventures, Illumina Ventures, Mubadala Capital, Qatar Investment Authority, Sequoia Capital, Tao Capital Partners, and other unspecified investors also participated in the round. The company plans to utilize the November 2025 funding to advance its AI-driven discovery and development platform for novel medicines.

## Funding rounds

- Series B, Nov 6, 2025, $99M — Abingworth, Hong Shan, Alexandria Venture Investments, WS Investments, Pegasus Tech Ventures, Alumni Ventures Group, Tao Capital Partners, Illumina Ventures, Mubadala Capital, Terra Magnum Capital Partners, Freeflow Ventures, Catalio Capital Management, Ark Invest, Ascenta Capital, Qatar Investment Authority, Regeneron Ventures, Everbright Biofund
- Series B, Jun 4, 2024, $8.5M — Abingworth, Nexus Venture Partners, Coatue Management, Tao Capital Partners, Illumina Ventures, Mubadala Capital, Exor Ventures, Qatar Investment Authority
- Series B, May 6, 2024, $3M — Alumni Ventures Group
- Series B, Sep 29, 2023, $103M — Abingworth, OrbiMed Advisors, Hong Shan, NVIDIA Corporation, Coatue Management, Alumni Ventures Group, Nexus Ventures, Illumina Ventures, Freeflow Ventures, Catalio Capital Management, Gradiant Corporation, Ascenta Capital
- Series A, Jul 14, 2021, $53M — OrbiMed Advisors, Hong Shan, Coatue Management, Nexus Ventures, Freeflow Ventures, Catalio Capital Management

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Hong Shan — Series A, Series B
- Coatue Management (https://capitalatlas.ai/funds/coatue-management) — Series A, Series B
- Nexus Ventures — Series A, Series B
- Freeflow Ventures (https://capitalatlas.ai/funds/freeflow-ventures) — Series A, Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series A, Series B
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series B
- NVIDIA Corporation — Series B
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series B
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series B
- Gradiant Corporation — Series B
- Ascenta Capital (https://capitalatlas.ai/funds/ascenta-capital) — Series B
- Nexus Venture Partners (https://capitalatlas.ai/funds/nexus-venture-partners) — Series B
- Tao Capital Partners (https://capitalatlas.ai/funds/tao-capital-partners) — Series B
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series B
- Exor Ventures — Series B
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- WS Investments (https://capitalatlas.ai/funds/ws-investments) — Series B
- Pegasus Tech Ventures (https://capitalatlas.ai/funds/pegasus-tech-ventures) — Series B
- Terra Magnum Capital Partners (https://capitalatlas.ai/funds/terra-magnum-capital-partners) — Series B
- Ark Invest (https://capitalatlas.ai/funds/ark-invest) — Series B
- Regeneron Ventures (https://capitalatlas.ai/funds/regeneron-ventures) — Series B
- Everbright Biofund (https://capitalatlas.ai/funds/everbright-biofund) — Series B